Roche obtained an exclusive worldwide licence for Rona’s experimental treatment targeting fat cells in obesity and metabolic disease. The deal combines RNA interference research with the Swiss group’s development and commercialisation capabilities. Further payments depend on development, regulatory and commercial milestones. The proposed benefits remain potential outcomes of an investigational therapy, with clinical efficacy still unproven.
Roche, the Swiss pharmaceutical group, obtained an exclusive worldwide licence for an experimental obesity and metabolic-disease treatment from Rona Therapeutics, a Chinese biotechnology company. The agreement announced on 13 October covers a candidate using RNA interference, a method that reduces the expression of a targeted gene. The treatment targets activin receptor-like kinase 7, known as ALK7.[1], [2]
Rona’s agreement provides up to 100 million dollars in upfront and near-term milestone payments combined. It also makes the company eligible for up to 1.06 billion dollars in additional development, regulatory and commercial milestones, plus tiered royalty revenue on worldwide net sales. Rona chief executive Stella Shi said the collaboration combines its research platform with Roche’s global development and commercialisation expertise.[1]
Rona’s delivery platform is designed to reach tissues outside the liver. The company says inhibiting ALK7 directly in fat cells could reduce visceral and other ectopic fat while preserving lean mass. These are potential benefits; clinical efficacy remains unproven. Rona sees possible use alone or alongside incretin-based treatments, which primarily affect appetite and energy intake. Roche describes the partnership as complementary to its cardiovascular, renal and metabolic pipeline.[1]
